MNDY vs NVDA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MNDY exhibits exceptional fundamental health with a perfect Piotroski F-Score of 9/9 and a very low Debt/Equity ratio of 0.14. While the stock has suffered a severe technical collapse over the last year (-74.9%), the valuation is now highly attractive with a PEG ratio of 0.28 and a Forward P/E of 12.26. The current price of $61.69 aligns closely with the growth-based intrinsic value of $66.08, suggesting a significant margin of safety relative to analyst targets of $125.76. The combination of 89.2% gross margins and consistent earnings beats makes this a high-conviction fundamental play despite the bearish price action.
NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.
Compare Another Pair
Related Comparisons
MNDY vs NVDA: Head-to-Head Comparison
This page compares monday.com Ltd. (MNDY) and NVIDIA Corporation (NVDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.